Redeye maintains its base case for Moberg Pharma after the report today, at SEK 27. The company steadily moves its projects forward, with two completed phase III studies sufficient for applying for registration in Europe, and secured funding for an additional study in the US, with a new design. We are optimistic about Moberg Pharma's ability to deliver.